Cancer Diagnostics Companies

Liquid Biopsy Gains Traction Companies like Guardant Health and GRAIL are leading the charge in developing minimally invasive liquid biopsy tests that detect cancer through circulating tumor DNA (ctDNA) in the bloodstream, paving the way for earlier diagnoses and personalized treatment options.

AI-Powered Diagnostics Companies like Paige AI and Intellisite are utilizing AI to analyze medical images and pathology slides with remarkable accuracy, assisting in cancer diagnosis and improving treatment decision-making.

Next-Gen Imaging Techniques Advancements in technologies like PET/CT and PET/MRI are providing more detailed and precise images of tumors, aiding in staging and treatment planning.

Roche acquires TIB MolBio for €1.8 billion move strengthens Roche's position in the molecular diagnostics market, particularly in liquid biopsy technologies, providing greater access to cancer testing solutions.

Illumina partners with Personalis collaboration combines Illumina's next-generation sequencing (NGS) expertise with Personalis' AI-powered data analysis platform, offering comprehensive genomic profiling for individualized cancer care.

QIAGEN collaborates with Invitae partnership focuses on developing and commercializing companion diagnostics for targeted cancer therapies, ensuring patients receive the most effective treatment based on their genomic profile.

List of Cancer Diagnostics Key Companies in the Market

• Exact Sciences Corporation


• Arquer Diagnostics Ltd


• BioMark Diagnostics Inc.


• Biotheranostics


• Agilent Technologies


• Thermo Fisher Scientific


• Illumina


• Becton Dickinson and Company (BD)


• GE Healthcare


• QIAGEN N.V.


• Abbott Laboratories